| Date | Time | Room | Session Title | Presentation Time | Topic | Role |
|---|---|---|---|---|---|---|
| 20/05/2023 | 09:25 to 11:30 | Di Cavalcanti |
Medical Medical Indolent Lymphomas |
09:50 to 10:08 | Problems on the horizon: when marginal zone lymphoma goes bad | Speaker |
| 20/05/2023 | 09:25 to 11:30 | Di Cavalcanti |
Medical Medical Indolent Lymphomas |
10:08 to 10:15 | Q&A | Discussant |
| 20/05/2023 | 09:25 to 11:30 | Di Cavalcanti |
Medical Medical Indolent Lymphomas |
11:05 to 11:23 | How do I treat Follicular lymphoma in the first and second line – the last gasps of cytotoxic therapies? | Speaker |
| 20/05/2023 | 09:25 to 11:30 | Di Cavalcanti |
Medical Medical Indolent Lymphomas |
11:23 to 11:30 | Q&A | Discussant |
| 20/05/2023 | 12:00 to 15:00 | Di Cavalcanti |
Medical Medical Aggressive Lymphomas |
12:25 to 12:43 | Going beyond the Deauville scale: extracting the most information from PET-CT and how it guides us in practice? | Speaker |
| 20/05/2023 | 12:00 to 15:00 | Di Cavalcanti |
Medical Medical Aggressive Lymphomas |
12:43 to 12:50 | Q&A | Discussant |
| 20/05/2023 | 12:00 to 15:00 | Di Cavalcanti |
Medical Medical Aggressive Lymphomas |
13:40 to 13:58 | Going beyond CODOX: how disease features may guide treatment in Burkitt’s lymphoma | Speaker |
| 20/05/2023 | 12:00 to 15:00 | Di Cavalcanti |
Medical Medical Aggressive Lymphomas |
13:58 to 14:05 | Q&A | Discussant |
| 20/05/2023 | 12:00 to 15:00 | Di Cavalcanti |
Medical Medical Aggressive Lymphomas |
14:30 to 15:00 | Round table: how to extract the best from conjugated or unconjugated monoclonal antibodies, chemotherapies, bispecific antibodies, and CAR-T in lymphomas? | Discussant |